Study S003222

A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function

ClinicalTrials.gov record

Registration

Registration: NCT07587710
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 35
Start: 2026-05-13
Primary completion: 2027-12-01
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:NNC0487-0111
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1320-4875; OTHER:2025-521647-20; NIH:2025

Registered primary outcomes

AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose [From pre-dose on Day 1 up to Day 28]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.